CAT-2054: Preliminary Phase I data

Preliminary data from a 2-part, double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 78 healthy volunteers showed that single and multiple doses of 50-1,000 mg oral CAT-2054 were w...